Mitchell Mathis is a Psychiatry physician affiliated with United States Food and Drug Administration. OpenAlex indexes 23 publications with 660 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10630 Little Patuxent Parkway
Suite 209
Columbia, MD 21044
Telephone
410-740-8066Registry record last updated 5 Apr 2012.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Benzodiazepine55.2%Clonazepam100%Part D<11 patientsPartial Opioid Agonist44.8%Buprenorphine Hcl57%Buprenorphine-Naloxone43%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues
The Journal of Clinical Psychiatry
2020 - Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration
Psychiatric Research and Clinical Practice
2020 - A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials
Clinical Pharmacology & Therapeutics
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Pazdur, MD
United States Food and Drug Administration
Marc Theoret, MD
United States Food and Drug Administration
Wellington Sun, MD
United States Food and Drug Administration
John Laschinger, MD
United States Food and Drug Administration
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”